The effect of Lorazepam on the anxiety of heart attack patients

Phase 3

Recruiting

• Conditions: Condition 1: STEMI. Condition 2: Anxiety.; ST elevation (STEMI) myocardial infarction of unspecified site; Anxiety disorder, unspecified; I21.3; F41.9

• Registration Number: IRCT20201102049232N3
• Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

ST Elevation Myocardial Infarction (STEMI) patients candidate for Primary Percutaneous Coronary Intervention (PPCI)

Exclusion Criteria

Patients who cannot take lorazepam because of Drug interactions, including alcohol; barbiturates; antipsychotics sedatives; hypnotics; anxiolytics; opioids; antidepressants; narcotics; analgesics; sedatives; antihistamines; anticonvulsants and anesthetics.
Patients who cannot take lorazepam because of lorazepam Contraindications including Allergy to Lorazepam; acute angle; closure glaucoma; severe respiratory depression and sleep apnea
Patients who cannot take lorazepam because of unconsciousness

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anxiety. Timepoint: First ward visit after Primary Percutaneous Coronary Intervention (PPCI). Method of measurement: Hospital Anxiety and Depression Scale (HADS) questionnaire.